Investigated
Can local hydrogel drug delivery treat arthritis?
Short answer
Image: pmc.ncbi.nlm.nih.gov
Local hydrogels can prolong drug residence in a joint and release anti-inflammatory or cartilage-targeting agents in response to disease signals. Animal studies are encouraging, but reviews identify major delivery barriers and no clinically available disease-modifying osteoarthritis therapy; these systems remain experimental rather than established treatment.
The views on this question
Two lenses on the same evidence. Source weight and the primary source ratio show what each rests on.
Alternative
Source weight 50%Lens adapted to this topic: Platform designs that target more than inflammation
A broader reading treats hydrogels not merely as drug depots but as multifunctional joint implants: adhesive and lubricating matrices may remain in the joint, respond to inflammatory enzymes, target activated immune cells, and support cartilage repair. Early studies report encouraging results, but these increasingly complex combinations require careful validation of persistence, toxicity, dosing, and clinical benefit.
- A bioadhesive, lubricating hydrogel combining hyaluronic-acid networks and a nanozyme-based cartilage-repair component was designed to address lubrication, inflammation, and cartilage wear in rheumatoid arthritis.
- An inflammation-responsive nanohydrogel was designed to release dexamethasone after matrix metalloproteinase activity and promote uptake by activated macrophages through CD44 targeting.
- A locally administered liposomal depot combined dexamethasone delivery with materials intended to inhibit inflammation and support cartilage repair in rheumatoid arthritis research.
- Chitosan-based hydrogel containing triptolide-loaded nanoparticles has also been investigated as a local rheumatoid arthritis treatment.
- The field is expanding toward injectable hydrogels with stimulus-responsive release and multiple therapeutic functions, rather than simple sustained-release depots.